Cemiplimab vs Pembrolizumab for Skin Cancer

It depends on which skin cancer you have. Pembrolizumab is the approved option in melanoma and in Merkel cell carcinoma. Cemiplimab is the approved option in basal cell carcinoma. In advanced cutaneous squamous cell carcinoma both are approved, and guideline bodies list either. The diagnosis decides the drug.

This is the part almost everything written about skin-cancer immunotherapy gets wrong, because it treats skin cancer as one disease. It is at least four. Melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma are staged differently, behave differently, and have different approved medicines. For two of those four, the choice between cemiplimab and pembrolizumab does not exist at all, because only one of the two is licensed for it.

So the useful question is not which drug is stronger. It is which cancer the pathology report names, and which of these two medicines carries an approval for it.

No. They are the same class — both PD-1 checkpoint inhibitors — but they are not substitutes for one another. Their approved indications only partly overlap, their dosing schedules differ, and in India only one of the two is routinely marketed. Swapping one for the other is a prescribing decision, never a pharmacy or family one.

For a family in Hyderabad, the difference that actually bites is usually the last two rows of that table rather than anything about the molecules. Pembrolizumab can be dispensed from a hospital pharmacy here. Cemiplimab has to be brought into the country for one named patient, on a prescription, with permissions and paperwork — a process measured in weeks, not days.

The two are not priced on the same basis in India, so a vial-to-vial comparison is misleading. Pembrolizumab has an Indian maximum retail price because it is marketed here. Cemiplimab has none, because it is not — its cost to an Indian family is a foreign list price plus an import layer.

Three things move the real number more than the headline vial figure. The first is how many cycles the protocol runs, which is decided at each response scan rather than at the start. The second is the six-weekly option: pembrolizumab can be given as 400 mg every six weeks in some settings, which does not lower the cost per week of drug much but does halve the number of hospital visits, and travel and leave are real costs for a family coming in from outside the city. The third is everything around the infusion — day-care charges, pre-cycle blood tests, consultations, and response-assessment PET-CT, which is generally coordinated at partner imaging centres rather than performed inside the treating unit and is billed separately.

Insurance behaves differently for the two as well. Cover for a medicine that is approved and marketed in India is easier to argue than cover for one that has to be imported, and many policies exclude medicines not approved and marketed here. Ask the insurer or the scheme desk for the position in writing before the first cycle, and ask specifically whether the drug, the day-care charge and the imaging are each covered.

In most skin cancers there is no choice to make, because only one of the two is approved. Where both are approved — advanced cutaneous squamous cell carcinoma — there is no head-to-head trial between them, and NCCN lists either as a systemic option. The decision then turns on prior treatment, the Indian label and what can actually be obtained.

No study has compared cemiplimab against pembrolizumab directly in skin cancer. That absence is the single most important fact on this page, because it means no article, no ranking and no oncologist can honestly say one is superior to the other in the setting where both apply. Each was tested against the standard of its time, not against the other.

In practice, being offered pembrolizumab rather than cemiplimab for advanced cutaneous squamous cell carcinoma in India is usually an availability decision, not a verdict on the molecules. One is on the hospital pharmacy shelf and one is not. That is a legitimate reason for a treating team to choose it, and it is worth asking the question plainly rather than assuming a clinical judgement was made against the drug you had read about.

The reverse also happens. If the diagnosis is basal cell carcinoma after a hedgehog pathway inhibitor, cemiplimab is the medicine with the approval, and the conversation moves from choosing a drug to arranging one — a different conversation, with a different timeline.

Broadly, no. Both release the same brake on the immune system, so both can cause immune-related adverse events in the gut, lungs, thyroid, liver, skin, heart or adrenal glands, at a broadly similar overall frequency. Neither has a meaningfully safer profile as a class matter.

What differs between them is practical rather than biological: how often you come in, and whether a six-weekly schedule is on the table. The organ risks are the class risks, and they are managed the same way — pre-cycle blood tests, and a low threshold for reporting a new symptom between cycles.

One thing does deserve a line of its own on medicines used mainly for skin cancer. The European Medicines Agency lists Stevens-Johnson syndrome and toxic epidermal necrolysis among the reactions reported with cemiplimab. A new rash that blisters, peels, or involves the mouth or eyes is not a minor skin complaint on either of these treatments, and it should never be assumed to be the skin cancer itself changing.

Symptoms that need urgent assessment rather than home management, on either medicine: new or worsening breathlessness or a persistent dry cough; loose motions increasing in number or containing blood; chest pain or palpitations; severe unexplained fatigue with dizziness, vomiting or collapse; yellowing of the eyes or skin; a blistering or peeling rash, or sores in the mouth or eyes. Contact your treating oncology team immediately or go to the nearest emergency department. Do not self-medicate, and do not wait for the next scheduled cycle. Tell any doctor who sees you, in any department, that you are on immunotherapy — it changes how these symptoms are investigated.

Five questions turn a comparison like this one into something usable in a consulting room.

1. Which skin cancer is this, exactly? Melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma are different diseases with different approved medicines.
2. Is the medicine you are proposing approved in India for this diagnosis, or would it have to be imported for me?
3. If it has to be imported, how long is that likely to take, and does it change the planned start date?
4. Is a six-weekly schedule an option here, and would it reduce the number of hospital visits?
5. What is the plan at the first response scan if the treatment is not doing anything?

The last one matters most for the money. Planning against a full two-year ceiling from day one is what pushes families into selling assets before they need to; budgeting to the first response assessment, usually after three or four cycles, is the honest decision point for the finances as well as the medicine.

If it is one of these two molecules specifically that you need to understand in depth, each has its own page: Cemiplimab (Libtayo): Uses and Availability in India goes further into the import route and the adjuvant setting, and Pembrolizumab (Keytruda): Uses, Dosing and Side Effects covers the wider indication list beyond skin.

If the comparison you actually need is between the two PD-1 medicines most often prescribed in India rather than these two, see Pembrolizumab vs Nivolumab: What Is the Difference?. For the brand-level cost and label picture in India, Keytruda vs Opdyta: Cost and Indications in India sets the two originator brands against each other, and Originator vs Biosimilar Nivolumab: Opdyta vs Tishtha explains what changes when a biosimilar enters — the price story that has not yet reached either of the drugs on this page.

For the full picture across checkpoint inhibitors, biosimilars, verification and cost, start from Immunotherapy Medicines Explained. For how immunotherapy works as a treatment rather than as a list of molecules, the main immunotherapy section is the place to begin.